[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344324-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344324-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","astatine-211-and-actinium-225-two-promising-nuclides-in-targeted-alpha-therapy","Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy","","Nuclear medicine therapy provides a strong strategy for tumor control by exploiting damage from radionuclide decay, and targeted alpha therapy (TAT) amplifies this effect with highly destructive alpha emissions while limiting toxic side effects. Astatine-211 (211At) and actinium-225 (225Ac) are highlighted as effective TAT agents owing to favorable physicochemical behavior and potent biological effects. The review summarizes applications of 211At-/225Ac radiopharmaceuticals across major tumor targets, integrating insights from preclinical and clinical trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/astatine-211-and-actinium-225-two-promising-nuclides-in-targeted-alpha-therapy/344324/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/astatine-211-and-actinium-225-two-promising-nuclides-in-targeted-alpha-therapy/344324.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",21,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is targeted alpha therapy considered promising for tumor treatment?","Question",{"text":63,"@type":64},"TAT uses alpha decay to generate intense, localized energy deposition that causes irreparable damage to tumor cells. Conjugation with targeted vectors can enhance tumor destruction while minimizing systemic toxicity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What makes Astatine-211 and Actinium-225 suitable for targeted alpha therapy?",{"text":68,"@type":64},"211At and 225Ac are described as highly effective due to exceptional physicochemical properties and strong biological effects. Their radionuclide characteristics support effective radiopharmaceutical performance.",{"name":70,"@type":61,"acceptedAnswer":71},"Which tumor targets are discussed for 211At-/225Ac radiopharmaceuticals?",{"text":72,"@type":64},"The review highlights applications including PSMA for prostate cancer, CD for hematological malignancies, HER2 for ovarian cancers, and SSTR for neuroendocrine tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344324,1790299758,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Review  \nAstatine-211 and actinium-225: two promising nuclides in targeted alpha therapy  \nDashan Zuo 1,2,3,†, Hui Wang 1,2,†, Boyi Yu 1,2, Qiang Li1,2,3,4, Lu Gan1,2,3, *, and Weiqiang Chen1,2,3,4, *  \n1 Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China, 2Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Gansu Province, Lanzhou 730000, China, 3University of Chinese Academy of Sciences, Beijing 100049, China,  \nand 4 Lanhai Nuclear Medical Research Center, Putian 351153, China †These authors contributed equally to this work.  \n*Correspondence address. Tel: +86-931-5196133; E-mail: [ganl@impcas.ac.cn](ganl@impcas.ac.cn) (L. G. ) / E-mail: [chenwq7315@impcas.ac.cn](chenwq7315@impcas.ac.cn) (W. C. ) Received 11 July 2024 Accepted 22 October 2024 Published 25 November 2024  \nAbstract  \nNuclear medicine therapy offers a promising approach for tumor treatment, as the energy emitted during radionuclide decay causes irreparable damage to tumor cells. Notably, α-decay exhibits an even more significant destructive potential. By conjugating α-nuclides with antibodies or small-molecule inhibitors, targeted alpha therapy (TAT) can enhance tumor destruction while minimizing toxic side effects, making TAT an increasingly attractive antineoplastic strategy. Astatine-211 (211At) and actinium-225 (225Ac) have emerged as highly effective agents in TAT due to their exceptional physicochemical properties and biological effects. In this review, we highlight the applications of 211At-/225Ac-radiopharmaceuticals, particularly in specific tumor targets, such as prostate-specific membrane antigen (PSMA) in prostate cancers, cluster of differentiation (CD) in hematological malignancies, human epidermal growth factor receptor-2 (HER2) in ovarian cancers, and somatostatin receptor (SSTR) in neuroendocrine tumors. We synthesize the progress from preclinical and clinical trials to provide insights into the promising potential of 211At-/225Ac-radiopharmaceuticals for future treatments.  \nKey words astatine-211, actinium-225, radiopharmaceuticals, cancer, targeted alpha therapy  \nIntroduction  \nFrom 1991 to 2021, the cancer mortality rate had a notable reduction of 33% . However, the incidence of cancer continues to increase, with malignant tumors being the second most formidable health threat to humans [1] . Nuclear therapy, particularly radioimmunologic drugs and small-molecule inhibitors, is a promising approach for treating small, diffuse, and micrometastatic tumors. The study of radioactivity originated in 1895 with Roentgen’s discovery of X-rays, and groundbreaking discoveries such as the identification of natural radiation, α-rays, and artificial radioactivity laid the foundation for synthesizing and utilizing radionuclides. The use of iodine-131 (131I) marked a pivotal milestone in radiation diagnosis and therapy, and various β-/γ-nuclides, such as fluorine- 18 (18F), yttrium-90 (90Y), gallium-68 (68Ga), iodine-125 (125I), iodine-131 (131I) and lutetium-177 (177Lu), have promoted significant advancements in nuclear medicine. Although radium-223  \n(223Ra) remains the sole α-nuclide approved by the Food and Drug  \nAdministration (FDA) for commercial use so far, targeted alpha therapy (TAT) holds immense clinical importance.  \nFirstly, α-nuclides decay releases energy ranging from 4 to 8 MeV within a limited range of approximately 100 μm, leading to high energy deposition, and the peak relative biological effect (RBE) occurs when the linear energy transfer (LET) approaches~100 keV/μm [2–4] . Secondly, the average ionization path length of α-particles in cells is closely comparable to the diameter of the deoxyribonucleic acid (DNA) double helix, potentially resulting in irreparable damage to genetic material. Moreover, their cytotoxicity remains unaffected mainly by dose or oxygen level, rendering them highly effective at eliminating hypoxic tumor cells [5] .  \nSo α-nuclides are predominantly em","cbCaib6Wgzpdx8JU","https://ap.wps.com/l/cbCaib6Wgzpdx8JU","pdf",1150806,17,"English","# Introduction\n## Targeted alpha therapy concept and rationale\n## Alpha- vs beta-nuclide properties\n## Targeting strategies using antibodies and chelators\n# Astatine-211 and actinium-225 radiopharmaceutical applications\n## Prostate cancers (PSMA)\n## Hematological malignancies (CD)\n## Ovarian cancers (HER2)\n## Neuroendocrine tumors (SSTR)\n# Preclinical and clinical progress\n## Translational insights for future treatment","[{\"question\":\"Why is targeted alpha therapy considered promising for tumor treatment?\",\"answer\":\"TAT uses alpha decay to generate intense, localized energy deposition that causes irreparable damage to tumor cells. Conjugation with targeted vectors can enhance tumor destruction while minimizing systemic toxicity.\"},{\"question\":\"What makes Astatine-211 and Actinium-225 suitable for targeted alpha therapy?\",\"answer\":\"211At and 225Ac are described as highly effective due to exceptional physicochemical properties and strong biological effects. Their radionuclide characteristics support effective radiopharmaceutical performance.\"},{\"question\":\"Which tumor targets are discussed for 211At-/225Ac radiopharmaceuticals?\",\"answer\":\"The review highlights applications including PSMA for prostate cancer, CD for hematological malignancies, HER2 for ovarian cancers, and SSTR for neuroendocrine tumors.\"}]","Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy | PDF",1790053394,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e2574d958852c57d7c2ad9cb460b090.webp",983,1269,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d28c1aca30a7f3058213e6348e304e7.webp",982,1268,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebabd626b156551fa578a127d433fb53.webp",981,1266,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17e48960e2da3c23c5c2be9a89441300.webp",980,1265]